Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KA2507 in Solid Tumors
NCT03008018Phase 1Completed
- Sponsor
- Karus Therapeutics
- Start
- Aug 2017
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of KA2507 in solid tumor, sponsored by Karus Therapeutics. Primary endpoint: Dose Limiting Toxicity at 28 days. Started Aug 2017; status: completed.
02
Drugs
KA2507
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03008018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03008018.